MedicalResearch.com Interview with: [caption id="attachment_60414" align="alignleft" width="162"] Dr. Greenhawt[/caption] Matthew Greenhawt, MD, MBA, MSc Professor of Pediatrics Section of Allergy and Immunology Director, Food Challenge and Research Unit Children’s Hospital Colorado University of Colorado School of Medicine Anschutz Medical Campus Aurora, CO 80045   MedicalResearch.com: What is the background for this study? Is the incidence of peanut allergy in toddlers stabilizing with the earlier introduction of peanuts? Response: There exists an urgent unmet medical need for infants and toddlers living with peanut allergy. Peanut allergy affects approximately 2% of U.S. children and has been a growing public health problem over the past 20 years. In fact, the number of kids affected by peanut allergy has tripled in that time span. Peanut allergy is not likely to be naturally outgrown, and reactions can be severe. However, there is hope. There is growing evidence that the allergic immune system is more modifiable early in life. The EPITOPE study evaluated Viaskin Peanut in children ages 1 – 3 years of age. Viaskin Peanut is an investigational epicutaneous immunotherapy (EPIT) product, which uses the skin as a route to desensitize a patient to be less reactive to peanut. This is a daily therapy, worn between the shoulders on the back, which allows for non-oral peanut desensitization, which many parents find highly appealing.